We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.

Delisted

BHVN was delisted on the 3rd of October, 2022.

7 hedge funds and large institutions have $13.8M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 229 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% less funds holding in top 10

Funds holding in top 10: 321 (-31)

97% less funds holding

Funds holding: 2407 (-233)

99% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 229

100% less capital invested

Capital invested by funds: $8.78B → $13.8M (-$8.77B)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
7
Holders Change
-233
Holders Change %
-97.08%
% of All Funds
0.11%
Holding in Top 10
1
Holding in Top 10 Change
-31
Holding in Top 10 Change %
-96.88%
% of All Funds
0.02%
New
2
Increased
Reduced
4
Closed
229
Calls
Puts
Net Calls
Net Calls Change

BHVN Hedge Fund Activity: Q4 2022 in Review

7 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q4 2022, worth a combined $13.8M — down 100% from $8.78B a quarter earlier.

Sellers outnumbered buyers: 229 funds closed out of BHVN and 2 opened new positions — a net loss of 227 holders — while 4 trimmed existing stakes and 0 added.

The largest buyer was Blue Trust Inc, opening a new position worth an estimated $9.87K. The largest seller was BlackRock, exiting entirely with an estimated $748M sold.

  • 7 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q4 2022, down from 240 in Q3 2022.
  • Funds reported $13.8M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q4 2022, down 100% quarter-over-quarter.
  • 2 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q4 2022 and 229 closed out, a net change of -227 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q4 2022 was Blue Trust Inc, an estimated $9.87K added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q4 2022 was BlackRock, an estimated $748M sold.

Based on aggregated 13F filings for Q4 2022.